Open AccessUp‐and‐Coming Markers: Myeloperoxidase, a Novel Biomarker Test for Heart Failure and Acute Coronary Syndrome Application?
Author(s) -
Sinning Christoph,
Schnabel Renate,
Peacock W. Frank,
Blankenberg Stefan
Publication year - 2008
Publication title -
congestive heart failure
Language(s) - English
Resource type - Journals
eISSN - 1751-7133
pISSN - 1527-5299
DOI - 10.1111/j.1751-7133.2008.08334.x
Subject(s) - myeloperoxidase , medicine , biomarker , heart failure , acute coronary syndrome , cardiology , coronary artery disease , disease , inflammation , cardiomyopathy , myocardial infarction , biochemistry , chemistry
Myeloperoxidase (MPO) is a mammalian enzyme responsible for generation of hypochlorite. The advantage of myeloperoxidase for use as a biomarker in the setting of heart failure and acute coronary syndrome is the early increase of MPO concentration in response to the acute event. In the setting of heart failure the reported independency of coronary artery disease and general inflammation, as indicated by MPO concentration in comparison to other inflammatory markers or in subgroups of patients with ischemic and non‐ischemic cardiomyopathy, has to be highlighted. In terms of ACS, inclusion of MPO into a multiple marker strategy might add to enhance diagnosis and therapy decision making. Therefore, MPO is a biomarker worthwhile of further evaluation in the setting of cardiovascular disease.